Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. - Test2 - elhamkhani - TriplyDB

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37988569

about

BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2 Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.Photochemical activation of drugs for the treatment of therapy-resistant cancers.Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.

P2860

Q31153995-9D50968A-3493-4B58-B7C7-02D7D7A800FA Q37263168-2C479819-BEBE-4833-A987-C16E06A4C2E1 Q37322437-51B1C59F-65B9-4ACE-8C80-4C1DA24F19D1 Q37636455-77DA6BD8-0177-40DA-87C6-B5D956AAC075 Q38255064-4D1D98B5-2ADF-4557-81AB-142DC9ED8EE7 Q38409528-0FA31AE8-1BAA-42BB-A7B3-DB4A5842B5DB Q38710822-626C8638-01B1-46A9-95A0-749B45805218 Q39143967-4A0765D0-4336-4091-BD4D-51CE1B1AF0A1 Q42586969-334EB114-FC27-45C3-80FE-5E268064734D Q47955211-59DA72BD-3301-4F0F-9EDB-0C369675C562

P2860

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37988569

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@en

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@nl

type

label

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@en

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@nl

prefLabel

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@en

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@nl

P1433

Q37988569-087125E3-0A10-4414-8508-955EBA521A57

P1476

Q37988569-BCFAAEBA-85C5-45F2-ABDE-4A545B3E1043

P2093

Q37988569-1A750039-026F-432A-BFB7-3E8E283F4281

P2860

Q37988569-033352C4-F808-4C2E-9FCC-9E76278F41FC

Q37988569-0623F2B9-5415-4EC5-BD3C-7E15D53E0D5B

Q37988569-0782116B-C4E5-4276-A6D9-AF1840C89B11

Q37988569-086B986E-93D4-4E52-95C8-24CB66563A35

Q37988569-0883A4A9-D706-4E17-B476-CCB218B2F37F

Q37988569-09F3F49C-EE8D-40DE-A1F3-24C190DBBC06

Q37988569-10ED75E3-50EF-4B09-88C2-1DE47F080498

Q37988569-118A3F65-8162-4533-BAC1-59046D058043

Q37988569-1255820A-B120-4D53-BBEE-FD6F0DE89871

Q37988569-149D0E35-DF95-4CEB-906C-F9D5302C329E

P304

Q37988569-8BEC4661-F47A-4232-9383-B53D739CB6DF

P31

Q37988569-DA5D8723-A0E5-4033-903A-8DC5A698B997

P356

Q37988569-F8CACBA3-8F79-4197-8C00-C377222CA2AC

P433

Q37988569-859B2232-48D2-4F46-850F-21652E0FF8B9

P478

Q37988569-F0289BAC-98CF-443C-838A-30E838540126

P50

Q37988569-4FB060DF-D274-4948-AE96-37369583CB5A

Q37988569-9EB6E7E7-BDD2-40C3-B745-9AACB850A311

P577

Q37988569-102B0BD4-E598-4290-9139-FC92038C2C0C

P5875

Q37988569-B45E5ADF-B7F5-4CE8-AB77-C81A037C8310

P698

Q37988569-F8BBEE4D-A8A4-4222-806A-36357F2491BA

P921

Q37988569-AAFEA804-34C7-4C8F-A3A7-31187CC847DF

Q37988569-C28C10F6-8107-458E-9157-F157C208BBBC

P356

P1433

Expert Review of Anticancer Therapy

P1476

Mechanisms and novel approache ...... e in chronic myeloid leukemia.

@en

P2093

Maria Karvela

http://www.w3.org/2001/XMLSchema#string

P2860

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Overriding imatinib resistance with a novel ABL kinase inhibitor

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

P304

381-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.10

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Tessa L Holyoake

G Vignir Helgason

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221865559

http://www.w3.org/2001/XMLSchema#string

P698

22369329

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia